Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives
Nanne K.H. de Boer, Markus F. Neurath(Friedrich-Alexander-Universität Erlangen-Nürnberg), Adriaan A. van Bodegraven(Maastricht University Medical Centre), Jeremy Sanderson(Guy's and St Thomas' NHS Foundation Trust), Imke Atreya(Friedrich-Alexander-Universität Erlangen-Nürnberg), Murray L. Barclay(University of Otago), Laurent Beaugerie(Assistance Publique – Hôpitaux de Paris), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Bindia Jharap(Meander Medisch Centrum), Anthony Lopez(Inserm), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Anthony M. Marinaki, Berrie Meijer(Amsterdam UMC Location Vrije Universiteit Amsterdam)
Cited by 94
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k